CatalystFDA/Bio

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

AIM highlights Ampligen's potential following FDA approval of Revolution Medicines' Daraxonrasib in pancreatic cancer.

What changed

AIM highlights Ampligen's potential following FDA approval of Revolution Medicines' Daraxonrasib in pancreatic cancer.

Why it matters

AIM highlights Ampligen's potential following FDA approval of Revolution Medicines' Daraxonrasib in pancreatic cancer. — impact context not separately stored; see What changed.

Sources

eodhd